NDA 206352 · Bristol Myers Squibb
Reyataz
Atazanavir Sulfate · Oral
Priority reviewLast checked: Nov 19, 2026Latest source record: Dec 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jun 2, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
216
68 Phase 3, 2 recruiting
FAERS reports
11,467
10,029 serious, 780 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 5, 2024.
REYATAZ ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. Limitations of Use: • REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations (8.4) ] . • Use of REYATAZ with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Microbiology (12.4) ] . REYATAZ is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. (1)
Mechanism: Atazanavir is an HIV-1 antiretroviral drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 23, 2017 Supplement 5 · Efficacy LetterLabel
- Sep 24, 2015 Supplement 3 · Efficacy · priority review LabelLetter
- Jun 2, 2014 Original approval · Type 3 - New Dosage Form · priority review LetterLabelReview
1 products under this application
- REYATAZ · ATAZANAVIR SULFATE EQ 50MG BASE/PACKET · POWDER, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Atazanavir" as an intervention, any sponsor and status, largest first.
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00118898 · 1,864 participants · Start Sep 2005 · Primary completion Nov 2009
Drug: Abacavir/Lamivudine; Atazanavir and 5 more · For: HIV Infections
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 52 sites in all
- Comparative Study of Three NNRTI-Sparing HAART RegimensPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00811954 · 1,814 participants · Start May 2009 · Primary completion Jun 2013
Drug: Emtricitabine/tenofovir disoproxil fumarate; Raltegravir and 3 more · For: HIV Infection
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 57 sites in all
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum WomenPivotal-lookingCompleted
International Maternal Pediatric Adolescent AIDS Clinical Trials GroupResearch network
NCT00955968 · 1,653 participants · Start Jan 1, 2010 · Primary completion Aug 31, 2016
Drug: Highly active antiretroviral therapy (HAART) · For: HIV Infection
Sites: Alhambra, California; Los Angeles, California; San Diego, California · 50 sites in all
- Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00084136 · 1,571 participants · Start May 2005 · Primary completion May 2010
Drug: Atazanavir; Didanosine (enteric-coated) and 4 more · For: HIV Infections
Sites: Los Angeles, California; Torrance, California; Denver, Colorado · 42 sites in all
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01815736 · 1,443 participants · Start Mar 27, 2013 · Primary completion Mar 16, 2015
Drug: E/C/F/TAF; E/C/F/TDF and 5 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 167 sites in all
Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
NCT02269917 · 1,149 participants · Start Mar 2015 · Primary completion Feb 2017
Drug: D/C/F/TAF; Boosted Protease Inhibitor (bPI) and 1 more · For: Human Immunodeficiency Virus Type 1
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 79 sites in all
- Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV InfectionPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00013520 · 1,125 participants
Drug: Abacavir sulfate, Lamivudine and Zidovudine; Atazanavir and 8 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 60 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction931
- anxiety759
- pain740
- foetal exposure during pregnancy718
- emotional distress651
- depression620
- anhedonia592
- renal failure453
- nephrolithiasis441
- nausea424
- fatigue395
- chronic kidney disease394
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 345 |
| 2005 | 459 |
| 2006 | 496 |
| 2007 | 362 |
| 2008 | 395 |
| 2009 | 598 |
| 2010 | 689 |
| 2011 | 769 |
| 2012 | 892 |
| 2013 | 623 |
| 2014 | 720 |
| 2015 | 808 |
| 2016 | 715 |
| 2017 | 553 |
| 2018 | 545 |
| 2019 | 608 |
| 2020 | 605 |
| 2021 | 499 |
| 2022 | 387 |
| 2023 | 207 |
| 2024 | 88 |
| 2025 | 66 |
| 2026 | 36 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Reyataz (Atazanavir Sulfate)
2024 spending
$650K
Beneficiaries
57
395 claims
Per beneficiary
$11,409
$38.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,299,539 |
| 2021 | $1,686,574 |
| 2022 | $1,337,506 |
| 2023 | $958,844 |
| 2024 | $650,335 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM, Gordi T, Zhong L, et al. · J Clin Pharmacol 2016 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005.
Toledo T, Oliveira VG, Cattani VB, et al. · Clin Pharmacokinet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions.
Awortwe C, Cascorbi I · Pharmacol Res 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
McDonald CK, Martorell C, Ramgopal M, et al. · HIV Clin Trials 2014 · Clinical Trial, Clinical Trial, Phase III
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.